Highlights of the report describe the company's quarterly report on April 25: the first quarter achieved revenue of 6021 million yuan, an increase of 67.22% year on year; net profit to mother was 10.61 million yuan, up 165.08% year on year; after deducting non-net profit of 9.988 million yuan, an increase of 168.45% year on year. Incident review: Shixuan continued to make efforts, laying the foundation for rapid growth throughout the year: the company achieved net profit of 1.0061 million yuan in the first quarter, and Shixuan's combined factors had a big impact. Shixuan's net profit for the first quarter of last year was 37.955 million yuan. After adjusting for consolidation factors, the company's original business and Shixuan's overall revenue increased 17.91% year on year, and overall net profit increased 38.30% year on year. The company's original main business is expected to maintain a slight increase. Shixuan's revenue growth rate is expected to reach 30% and net profit growth rate to reach 50% in the first quarter. It continues to show a rapid growth trend, laying the foundation for rapid growth throughout the year. We believe that the growth rate of the company's medical informatization business is expected to continue: first, the scope of its business is mainly in key prefecture-level cities in non-provincial capitals, and the need to raise the level of informatization is urgent, and the catch-up effect continues to be reflected; second, the Shixuan product line covers HIS, CIS, regional medical informatization and personal health management, etc., and has a good synergy and mutual penetration effect; third, since September 2015, the State Council's focus on deploying hierarchical diagnosis and treatment systems has also added strong impetus to its regional medical informatization platform construction business. Product sales are expected to expand rapidly, medical layout or a new starting point: Daqian Biotech has a total of 90 medical device registration certificates, and has the ability to provide the most complete laboratory solutions for various medical institutions. Its business covers 26 provinces, cities, and autonomous regions across the country. It is already a powerful medium-sized IVD manufacturer; Exxon Biotech's independent product development has been completed, and the performance explosion is worth looking forward to. Daqian and Exxon's high-quality products are expected to use Shixuan's broad platform and rich customer resources to achieve rapid expansion of high-quality channels. The investment of 50 million yuan to establish an industrial investment company is an important signal to accelerate the layout of the medical sector. Using professional teams to expand business areas and investment channels, or usher in a new starting point in related business layout. The development prospects are worth looking forward to. Accelerated integration is just around the corner, maintaining a “buy” rating. The company has excellent quality, stable traditional business, and strong medical business synergy. Since transforming the medical business, it has continued to grow rapidly. The establishment of an industrial investment company may be an important sign to accelerate the layout. EPS is expected to be 0.5 yuan, 0.75 yuan, and 0.92 yuan in 2016, 2017, and 2018, maintaining a “buy” rating. Risk Warning: Business is not progressing as fast as expected